Zelluna ASA (OB: ZLNA)
Health Care · Biotechnology · NO
Nkr21.00
-7.08% today · +55.6% 1Y
Zelluna ASA (OB: ZLNA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $65.43M and employs 24 people.
Over the last twelve months the share price has gained 55.6%, trading between 8.20 and 35.80.
Tweenvest scores Zelluna ASA across four factors: quality 28/100. Its strongest factor is quality.
ZLNA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $65.43M
- Revenue (TTM)
- $821.00
- P/E
- —
- EPS
- -5.42
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- Nkr35.80
- 52-week low
- Nkr8.20
- Avg volume (3M)
- —
- Shares outstanding
- 29.41M
- Employees
- 24
- Next earnings
- —
About Zelluna ASA
Established in 2016 and headquartered in Oslo, Norway, Zelluna ASA specializes in the creation of T-cell receptor (TCR) cellular immunotherapy treatments aimed at combating solid tumors.
- ISIN
- NO0013524942
- Founded
- 2016
- Listed since
- Jun 3, 2019
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.72 | +0.35% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.50 | -0.21% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.